New immunotherapy combo tested before surgery for various cancers
NCT ID NCT06279130
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing two immunotherapy drugs, botensilimab and balstilimab, given before surgery to people with resectable solid tumors that are either mismatch repair deficient (dMMR) or proficient (pMMR). The goal is to see if this combination can shrink tumors significantly, measured by how much viable tumor remains after surgery. About 133 adults with non-metastatic cancers will participate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
botensilimab and balstilimab (immunotherapy drugs)
What this could lead to
If successful, this could show that combining these immunotherapies before surgery helps shrink or eliminate tumors in multiple cancer types, potentially improving outcomes.
What could go wrong
This is a mid-stage trial with only 133 participants, and results may not apply to all cancers. Immunotherapies can cause immune-related side effects, and not all patients may respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE MMR-DEFICIENT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Netherlands Cancer Institute
RECRUITINGAmsterdam, North Holland, 1066 CX, Netherlands
Contact
Contact